ANSWER: C

Rationale:

Ethinyl estradiol (EE) differs from natural 17-beta-estradiol by the addition of an ethinyl group at the 17-alpha position of the steroid D-ring. This substitution sterically hinders the hepatic oxidative metabolism that rapidly inactivates natural estradiol during first pass through the liver. As a result, EE retains substantial oral bioavailability and has a markedly prolonged half-life compared to natural estradiol, which is why EE rather than estradiol became the standard estrogen of oral contraceptives. This pharmacokinetic advantage comes with a clinically important cost: because EE is so resistant to hepatic clearance and produces strong hepatic estrogenic effects, it drives synthesis of coagulation factors and angiotensinogen more potently than transdermal or natural estradiol preparations, contributing to its VTE and blood pressure effects.

• Option A: Option A is incorrect because EE is not sulfate-conjugated to prevent absorption — it is well absorbed orally, and its oral activity derives from resistance to hepatic metabolism, not from any requirement for sublingual administration.
• Option B: Option B is incorrect because EE is not a prodrug — it is itself the active estrogen and binds the estrogen receptor directly; it does not require conversion to 17-beta-estradiol (in fact, the relationship runs the other way, as estradiol valerate is the prodrug that releases natural estradiol).
• Option D: Option D is incorrect because EE is extensively metabolized by the liver (via CYP3A4 oxidation and UGT glucuronidation) rather than being excreted unchanged — this hepatic metabolism is precisely why EE is subject to the drug interactions with enzyme inducers covered elsewhere in this module.
• Option E: Option E is incorrect because EE retains the phenolic A-ring characteristic of estrogens (required for estrogen receptor binding) and is absorbed through the portal circulation with hepatic first-pass exposure, not via lymphatic absorption bypassing the liver.

ANSWER: A

Rationale:

Spinnbarkeit (from the German for "spinnability" or "stretchability") describes the fluid, elastic, highly stretchable quality of cervical mucus at mid-cycle, when it can be drawn into long threads between two surfaces. This quality is driven by rising estradiol in the late follicular phase and represents the maximally sperm-penetrable state of cervical mucus, physiologically optimized to facilitate sperm transport at the time of ovulation. The contraceptive relevance is that progestins reverse this state: under progestin dominance, cervical mucus loses its spinnbarkeit and becomes thick, viscous, scant, and impenetrable to sperm — this progestin-driven reversal is the cervical mucus contraceptive mechanism shared by combined and progestin-only methods. Understanding spinnbarkeit as the estrogen-driven, sperm-favorable baseline clarifies why progestins (which oppose it) are the agents responsible for the cervical contraceptive effect.

• Option B: Option B is incorrect because it inverts the definition — spinnbarkeit is the fluid, penetrable, estrogen-driven state, not the thick progestin-driven impenetrable state; the progestin-produced impenetrable mucus is the loss of spinnbarkeit, not spinnbarkeit itself.
• Option C: Option C is incorrect because, while ferning is also an estrogen-dependent property of dried cervical mucus, spinnbarkeit specifically refers to the stretchability of fresh mucus and is directly related to sperm penetrability and hormonal status; the two are related estrogen markers but spinnbarkeit is not the ferning pattern and is not unrelated to penetrability.
• Option D: Option D is incorrect because spinnbarkeit refers to the physical stretchability of mucus, not resistance to seminal proteases, and it is driven by estradiol rather than ethinyl estradiol in physiological terms; EE in contraceptives does not enhance spinnbarkeit because the progestin component dominates the cervical effect.
• Option E: Option E is incorrect because spinnbarkeit refers to mucus stretchability, not pH — and it is an estrogen-driven follicular-phase property, not a progesterone-driven luteal-phase one; the description of acidic luteal pH is unrelated to the definition of spinnbarkeit.

ANSWER: D

Rationale:

Etonogestrel (chemically 3-ketodesogestrel) is the biologically active metabolite of desogestrel. When desogestrel is taken orally — for example, in the desogestrel 75-microgram progestin-only pill — it is rapidly converted by hepatic metabolism to etonogestrel, which is the moiety responsible for the progestational activity. Etonogestrel is also the progestin delivered directly by the etonogestrel subdermal implant (Nexplanon) and is the progestin component of the combined contraceptive vaginal ring (etonogestrel plus ethinyl estradiol). Recognizing this relationship explains why the desogestrel POP and the etonogestrel implant share a similar pharmacological profile and why both reliably suppress ovulation: they deliver the same active progestin to the systemic circulation, differing principally in the route and duration of delivery.

• Option A: Option A is incorrect because desogestrel and etonogestrel are directly related — etonogestrel is the active metabolite of desogestrel, not an unrelated compound; they are pharmacologically linked through the desogestrel-to-etonogestrel conversion.
• Option B: Option B is incorrect because it inverts the metabolic relationship — desogestrel is the prodrug and etonogestrel is the active metabolite, not the reverse; etonogestrel is not converted to desogestrel.
• Option C: Option C is incorrect because etonogestrel is not restricted to injectable depot formulations — it is delivered by the subdermal implant and the combined vaginal ring, and its prodrug desogestrel is used in oral progestin-only pills; there is no injectable depot etonogestrel product, and DMPA uses medroxyprogesterone acetate rather than etonogestrel.
• Option E: Option E is incorrect because etonogestrel is the active metabolite of desogestrel, not of levonorgestrel, and norethindrone is not metabolized to desogestrel — levonorgestrel and norethindrone are distinct progestins with their own pharmacology unrelated to the desogestrel/etonogestrel pair.

ANSWER: B

Rationale:

Ulipristal acetate (UPA) is a selective progesterone receptor modulator (SPRM) — it binds the progesterone receptor (PR) and exhibits tissue-selective partial agonist and antagonist activity, with the predominant effect in a given tissue determined by the local coactivator and corepressor environment. In the context of emergency contraception, UPA's antagonist activity at the PR in the hypothalamic-pituitary axis is what allows it to inhibit or delay follicular rupture even after the LH surge has begun. Levonorgestrel (LNG), by contrast, is a progestin that acts as a progesterone receptor agonist; its emergency contraception mechanism is suppression of the LH surge through progestogenic feedback before the surge peaks, which is why it loses efficacy once the surge is underway. This fundamental class difference — SPRM versus progestin agonist — explains UPA's longer efficacy window and its post-LH-surge activity.

• Option A: Option A is incorrect because UPA is not a pure progesterone receptor agonist — it is an SPRM with partial agonist/antagonist activity; only LNG among these two is a progestin agonist.
• Option C: Option C is incorrect because UPA is not a pure antagonist with no agonist activity — it is a selective receptor modulator with tissue-dependent partial agonist and antagonist effects, distinguishing it pharmacologically from a pure antiprogestin; while UPA and mifepristone are both SPRMs/antiprogestins, UPA retains tissue-selective partial agonism and is not described as a pure antagonist.
• Option D: Option D is incorrect because it inverts the classification — UPA is the SPRM and LNG is the progestin agonist, not the reverse; levonorgestrel has no selective progesterone receptor modulator activity.
• Option E: Option E is incorrect because neither UPA nor LNG is a selective estrogen receptor modulator — both act at the progesterone receptor, not the estrogen receptor; SERMs such as tamoxifen and raloxifene are a separate class acting on estrogen receptors and are unrelated to these emergency contraceptives.

ANSWER: E

Rationale:

The Pearl Index is the most widely used measure of contraceptive efficacy. It expresses the number of contraceptive failures (unintended pregnancies) per 100 woman-years of exposure to the method — equivalently, the number of pregnancies that would occur if 100 women used the method for one year. A lower Pearl Index indicates higher efficacy: the etonogestrel implant has a Pearl Index below 0.1, DMPA below 0.3 with perfect use, and combined oral contraceptives approximately 0.3 with perfect use but substantially higher with typical use. The Pearl Index allows direct comparison of methods on a common scale and is reported separately for perfect use and typical use to capture the impact of adherence.

• Option A: Option A is incorrect because the percentage of women discontinuing a method within the first year is the discontinuation rate, a separate measure of acceptability and tolerability, not the Pearl Index, which measures contraceptive failure.
• Option B: Option B is incorrect because the Pearl Index is not a ratio of perfect-use to typical-use failure rates — it is an absolute failure rate per 100 woman-years, reported separately for perfect and typical use rather than as a ratio between them.
• Option C: Option C is incorrect because the number of days of backup contraception needed after a missed dose is a clinical dosing instruction unrelated to the Pearl Index, which is a population-level efficacy measure.
• Option D: Option D is incorrect because percentage reduction in expected pregnancy rate compared to no contraception is the way emergency contraception efficacy is often expressed, but it is not the definition of the Pearl Index, which is an absolute count of pregnancies per 100 woman-years for ongoing methods.

ANSWER: C

Rationale:

Rifampin induces drug-metabolizing enzymes primarily through activation of the pregnane X receptor (PXR), a ligand-activated nuclear transcription factor that functions as a xenobiotic sensor. When rifampin binds and activates PXR, the receptor upregulates transcription of a battery of genes involved in drug metabolism and elimination, including CYP3A4 (the major enzyme metabolizing ethinyl estradiol and many progestins), CYP2C9, and the efflux transporter P-glycoprotein. The resulting increase in metabolic capacity reduces the plasma concentrations of ethinyl estradiol and progestins, compromising contraceptive efficacy. PXR is the central mediator of the most clinically important contraceptive drug interactions, including those caused by rifampin, rifabutin, and several enzyme-inducing antiepileptic drugs.

• Option A: Option A is incorrect because, while the constitutive androstane receptor (CAR) does contribute to enzyme induction by some agents and there is crosstalk between CAR and PXR, rifampin is a prototypical PXR agonist, and CAR is not the sole mediator of rifampin induction; the primary receptor for rifampin is PXR.
• Option B: Option B is incorrect because the aryl hydrocarbon receptor (AhR) mediates induction of CYP1A enzymes by polycyclic aromatic hydrocarbons (such as those in cigarette smoke and char-grilled food), not the CYP3A4 induction produced by rifampin; AhR is not the receptor rifampin activates.
• Option D: Option D is incorrect because rifampin does not act as a glucocorticoid agonist at the glucocorticoid receptor to induce CYP3A4 — its induction is mediated by PXR; the glucocorticoid receptor is not the mechanism of rifampin enzyme induction.
• Option E: Option E is incorrect because rifampin does not activate estrogen receptor alpha, and there is no negative feedback loop by which estrogen receptor activation accelerates EE clearance; the reduction in EE levels results from PXR-mediated upregulation of metabolizing enzymes, not from estrogen receptor signaling.

ANSWER: A

Rationale:

The operational distinction between WHO MEC Category 3 and Category 4 is clinically decisive. Category 3 means the theoretical or proven risks generally outweigh the advantages of using the method — the method is not recommended, but it may be used when no other acceptable or available option exists, requiring careful clinical judgment and follow-up. Category 4 means the method represents an unacceptable health risk and constitutes an absolute contraindication — it must not be used under any circumstances, regardless of whether alternatives are available. The practical implication is that a Category 3 designation leaves a narrow door open for use in constrained circumstances, whereas a Category 4 designation closes that door entirely. For example, combined hormonal methods are Category 3 in a woman over 35 who smokes fewer than 15 cigarettes per day (usable only if no acceptable alternative exists) but Category 4 in a woman over 35 who smokes more than 15 cigarettes per day (never usable).

• Option B: Option B is incorrect because it describes Category 2 (advantages outweigh risks, use freely) for the Category 3 definition and mischaracterizes Category 4 as a balanced shared-decision situation, which is wrong — Category 4 is an absolute contraindication, not a balanced risk-benefit scenario.
• Option C: Option C is incorrect because Category 3 and Category 4 are not clinically equivalent — Category 3 permits use when no alternative exists, while Category 4 does not; the numbering reflects increasing risk severity, not the order of addition to the guideline.
• Option D: Option D is incorrect because the WHO MEC categories describe clinical safety in the presence of specific conditions, not investigational or market-withdrawal status; neither Category 3 nor Category 4 refers to regulatory or marketing status.
• Option E: Option E is incorrect because Category 3 does not mean the method is preferred (that would be Category 1), and Category 4 does not mean second-line but acceptable — Category 4 is an absolute contraindication, the opposite of an acceptable second-line option.

ANSWER: D

Rationale:

The copper IUD exerts its contraceptive effect through the local release of copper ions into the uterine cavity and surrounding fluids. Copper ions are directly cytotoxic to spermatozoa, impairing sperm motility and viability so that sperm are unable to reach or fertilize the ovum. Copper also induces a local sterile inflammatory reaction in the endometrium that is hostile to both sperm and, secondarily, to fertilization and implantation. Critically, this mechanism is entirely non-hormonal and independent of ovulation — the copper IUD does not suppress the HPO axis, does not alter ovulatory cycles, and works regardless of where the woman is in her cycle. This is precisely why the copper IUD is effective as emergency contraception even after ovulation has occurred and why its efficacy is independent of body weight and unaffected by drug interactions that compromise hormonal methods.

• Option A: Option A is incorrect because the copper IUD contains no progestin and releases no hormone — progestin release describes the levonorgestrel-IUD, a different device; the copper IUD's mechanism is copper ion cytotoxicity, not hormonal.
• Option B: Option B is incorrect because the copper IUD does not work by mechanically obstructing the fallopian tubes — it sits within the uterine cavity and works through copper ion effects on sperm, not by physical tubal blockade.
• Option C: Option C is incorrect because the copper IUD does not produce clinically meaningful systemic copper absorption and does not suppress the HPO axis or inhibit ovulation — its action is entirely local within the uterine cavity, and ovulation continues normally in copper IUD users.
• Option E: Option E is incorrect because the copper IUD does not work by triggering expulsive withdrawal bleeding — its mechanism is copper ion cytotoxicity to sperm preventing fertilization, not mechanical expulsion of an implanted embryo through heavy menses.

ANSWER: B

Rationale:

Lamotrigine is inactivated primarily by Phase II glucuronidation, and the principal enzyme responsible is uridine diphosphate glucuronosyltransferase 1A4 (UGT1A4). Ethinyl estradiol is a potent inducer of UGT1A4. When a woman stabilized on lamotrigine begins an ethinyl estradiol-containing combined hormonal method, induction of UGT1A4 accelerates lamotrigine glucuronidation and reduces lamotrigine plasma concentrations by 40 to 65%, risking loss of seizure control. Conversely, when the EE-containing method is stopped (or during the hormone-free interval of a cyclic regimen), UGT1A4 activity falls and lamotrigine levels rebound, risking toxicity. Because the interaction is mediated by a Phase II glucuronidation enzyme rather than an oxidative CYP enzyme, it is specific to drugs cleared by glucuronidation and is why progestin-only methods (which contain no EE) do not affect lamotrigine.

• Option A: Option A is incorrect because lamotrigine is not primarily cleared by CYP3A4 oxidation — its principal inactivation route is UGT1A4-mediated glucuronidation; the EE-lamotrigine interaction is a glucuronidation interaction, not a CYP3A4 oxidative one.
• Option C: Option C is incorrect because CYP2C9 is not the enzyme responsible for lamotrigine inactivation — lamotrigine is glucuronidated by UGT1A4; while EE and rifampin can affect CYP2C9, that enzyme is not the mediator of the lamotrigine interaction.
• Option D: Option D is incorrect because thiopurine methyltransferase (TPMT) metabolizes thiopurine drugs such as azathioprine and mercaptopurine, not lamotrigine, and is unrelated to ethinyl estradiol; lamotrigine is not methylated by TPMT.
• Option E: Option E is incorrect because monoamine oxidase A (MAO-A) deaminates monoamine neurotransmitters and certain amine drugs, not lamotrigine, and is not induced by ethinyl estradiol; lamotrigine inactivation is by glucuronidation, not deamination.

ANSWER: E

Rationale:

Depot medroxyprogesterone acetate (DMPA) is administered as either 150 mg intramuscularly every 12 weeks or 104 mg subcutaneously every 13 weeks. Both formulations provide depot release of medroxyprogesterone acetate (MPA) from the injection site, maintaining contraceptive serum concentrations across the full dosing interval and suppressing ovulation within 24 hours of the first injection. The intramuscular 150 mg every-12-week regimen is the long-established standard; the subcutaneous 104 mg every-13-week formulation was developed to allow lower-dose delivery and the possibility of patient self-administration. Knowing these regimens is foundational for counseling on injection scheduling and for recognizing that DMPA is a quarterly method requiring a provider visit or self-injection every 3 months.

• Option A: Option A is incorrect because DMPA is not an oral medication — it is a depot injectable; there is no oral DMPA contraceptive regimen, and the depot route is essential to its sustained-release pharmacokinetics.
• Option B: Option B is incorrect because DMPA is not dosed weekly or every 2 weeks in milligram quantities of 5 to 10 mg — the depot formulation is given quarterly at much higher doses (150 mg IM or 104 mg SC) to achieve sustained release over 12 to 13 weeks.
• Option C: Option C is incorrect because the doses and intervals are wrong — DMPA is 150 mg IM every 12 weeks, not 300 mg every 6 months, and the subcutaneous dose is 104 mg every 13 weeks, not 150 mg every 3 months.
• Option D: Option D is incorrect because 1.5 mg describes the levonorgestrel emergency contraception dose, not DMPA; DMPA is given at 150 mg IM or 104 mg SC on a quarterly schedule, not as a small monthly milligram dose.

ANSWER: A

Rationale:

The norethindrone 0.35 mg minipill has a strict 3-hour missed-pill window. Because it does not reliably suppress ovulation and depends primarily on continuous cervical mucus thickening, any lapse in plasma norethindrone allows cervical mucus permeability to recover within 3 to 4 hours; a pill taken more than 3 hours late therefore requires backup contraception. The desogestrel 75-microgram pill has a more forgiving 12-hour window. Desogestrel is converted to etonogestrel, which reliably suppresses ovulation and maintains plasma concentrations above the ovulation-suppression threshold across a 12-hour interval, giving a missed-pill window comparable to that of combined oral contraceptives. This distinction has direct clinical importance: the desogestrel pill is a more error-tolerant progestin-only option for women who may not dose at a precise time each day.

• Option B: Option B is incorrect because the two pills do not share identical pharmacokinetics or an identical window — norethindrone has a 3-hour window and desogestrel a 12-hour window, reflecting their different mechanisms (cervical mucus dependence versus reliable ovulation suppression).
• Option C: Option C is incorrect because it inverts and misstates the windows — norethindrone has the strict 3-hour window (not 24 hours) and desogestrel has the 12-hour window (not 3 hours); the desogestrel pill is more forgiving, not less.
• Option D: Option D is incorrect because the desogestrel pill's 12-hour window applies to the progestin-only desogestrel formulation itself and does not require combination with ethinyl estradiol — the wider window arises from reliable ovulation suppression by etonogestrel, not from any estrogen component.
• Option E: Option E is incorrect because progestin-only pills do have defined missed-pill windows and do lose efficacy with sufficiently delayed dosing — the entire clinical distinction between these two formulations rests on their different missed-pill windows.

ANSWER: C

Rationale:

The LNG-IUD works primarily through local progestogenic effects within the uterine cavity. The device delivers high concentrations of levonorgestrel directly to the endometrium, producing marked decidualization followed by glandular atrophy that renders the endometrium unsuitable for implantation, and it thickens cervical mucus to an impenetrable state through local progestin action. Although the 52 mg device does suppress ovulation in about half of cycles in the first year, this proportion falls below 25% by year 5 — meaning that for most of the device's lifespan, ovulation continues, and the dominant contraceptive mechanism is the local endometrial and cervical effect rather than ovulation suppression. This local mechanism, achieved at systemic levonorgestrel concentrations far lower than those produced by oral levonorgestrel pills (approximately 150 to 200 picograms per milliliter for the 52 mg device), explains both the high efficacy of the LNG-IUD and its minimal systemic progestogenic side effects.

• Option A: Option A is incorrect because systemic HPO axis suppression is not the primary mechanism and ovulation suppression is not consistent throughout the device's lifespan — ovulation suppression falls below 25% of cycles by year 5, so the local uterine effects dominate.
• Option B: Option B is incorrect because the LNG-IUD's mechanism is hormonal (local progestin effects on endometrium and cervical mucus), not a non-hormonal foreign-body reaction; the copper IUD works by copper ion cytotoxicity, a fundamentally different and non-hormonal mechanism.
• Option D: Option D is incorrect because the LNG-IUD does not work by acidifying the uterine cavity or through directly spermicidal metabolites — its mechanism is local progestogenic endometrial and cervical mucus effects, not chemical acidification.
• Option E: Option E is incorrect because systemic levonorgestrel levels with the LNG-IUD are far lower than those produced by oral levonorgestrel pills — this is precisely why the LNG-IUD produces minimal systemic side effects and does not rely on systemic ovulation suppression for its efficacy.

ANSWER: D

Rationale:

Integrase strand-transfer inhibitors (INSTIs), including dolutegravir, raltegravir, elvitegravir (when not cobicistat-boosted), and bictegravir, do not meaningfully alter the pharmacokinetics of ethinyl estradiol or progestins. They neither induce nor inhibit the enzymes responsible for contraceptive steroid metabolism to a clinically significant degree, making them the preferred antiretroviral class for a woman who wants to rely on hormonal contraception. Rilpivirine, an NNRTI, is similarly contraceptive-neutral, but as a class the INSTIs are the cleanest choice. This contrasts with the enzyme-inducing and EE-lowering effects of several other antiretroviral agents and is an important consideration when an HIV treatment regimen is being selected for a woman who also requires effective contraception.

• Option A: Option A is incorrect because the NNRTIs efavirenz and nevirapine are potent CYP3A4 inducers that reduce ethinyl estradiol and progestin AUCs by 40 to 60%, compromising hormonal contraceptive efficacy — they are not contraceptive-neutral (note that the NNRTI rilpivirine is an exception, but efavirenz and nevirapine are not).
• Option B: Option B is incorrect because ritonavir-boosted protease inhibitors paradoxically reduce ethinyl estradiol AUC by approximately 40 to 50% through induction of EE glucuronidation, making combined hormonal methods unreliable — they do meaningfully reduce contraceptive steroid levels.
• Option C: Option C is incorrect because cobicistat, used as a pharmacokinetic booster, similarly reduces ethinyl estradiol exposure and renders combined hormonal methods unreliable — cobicistat-boosted regimens are not contraceptive-neutral.
• Option E: Option E is incorrect because rifamycin-class agents (rifampin, rifabutin) are potent enzyme inducers via PXR activation that substantially reduce ethinyl estradiol and progestin concentrations — they are among the most consequential drugs reducing hormonal contraceptive efficacy, the opposite of contraceptive-neutral.

ANSWER: B

Rationale:

Within the ethinyl estradiol-containing combined pill class, second-generation progestins — levonorgestrel and norgestrel — carry the lowest VTE risk, particularly at low EE doses such as 20 micrograms. Third-generation progestins — desogestrel, gestodene, and norgestimate — are associated in multiple large epidemiological studies with approximately 1.5 to 2 times the VTE risk of levonorgestrel-containing formulations, attributed to differential effects on activated protein C resistance and coagulation factor profiles. This generational distinction is the basis for the common clinical recommendation that a woman at modestly elevated baseline VTE risk who chooses a combined pill should preferentially receive a low-dose levonorgestrel formulation.

• Option A: Option A is incorrect because it inverts the relationship — third-generation progestins do not carry the lowest VTE risk; they carry higher VTE risk than second-generation levonorgestrel-containing pills, despite their more favorable androgenic and lipid profiles.
• Option C: Option C is incorrect because first-generation progestins do not carry zero VTE risk and later generations do not all carry identical risk — the meaningful, replicated distinction is the higher VTE risk of third-generation versus second-generation progestins, not an all-or-none first-generation effect.
• Option D: Option D is incorrect because progestin generation does independently influence VTE risk beyond the EE dose effect — at the same EE dose, third-generation formulations carry higher VTE risk than levonorgestrel-containing ones, a finding confirmed across multiple datasets.
• Option E: Option E is incorrect because drospirenone is not a second-generation progestin and does not carry the lowest VTE risk — drospirenone-containing pills are associated with VTE risk comparable to or higher than third-generation formulations and higher than levonorgestrel-containing pills.

ANSWER: E

Rationale:

Levonorgestrel emergency contraception has a practical efficacy window of 72 hours (3 days) after unprotected intercourse, with efficacy highest within the first 24 hours and declining substantially by 48 to 72 hours. Because levonorgestrel works only by suppressing the LH surge before it peaks, it becomes ineffective once ovulation is imminent or has occurred. Ulipristal acetate (UPA) extends the window to 120 hours (5 days) because, as a selective progesterone receptor modulator, it can inhibit or delay follicular rupture even after the LH surge has already begun — a capability levonorgestrel lacks. This mechanistic difference is the reason for UPA's longer window and its superior efficacy when treatment is delayed beyond 72 hours. Knowing these windows is foundational for selecting the appropriate agent based on the time elapsed since intercourse.

• Option A: Option A is incorrect because it inverts the windows — levonorgestrel has the shorter 72-hour window and ulipristal acetate the longer 120-hour window, not the reverse; levonorgestrel does not retain efficacy for 120 hours.
• Option B: Option B is incorrect because the two agents do not share an identical 24-hour window — levonorgestrel's window is 72 hours and ulipristal acetate's is 120 hours, and efficacy is highest early but persists well beyond 24 hours for both.
• Option C: Option C is incorrect because it reverses the agents — levonorgestrel has the 72-hour (not 5-day) window, and ulipristal acetate has the 120-hour (5-day) window, not a 12-hour limit.
• Option D: Option D is incorrect because neither agent retains efficacy for 10 days — the windows are 72 hours for levonorgestrel and 120 hours for ulipristal acetate, and there is a meaningful difference between them; only the copper IUD remains effective up to 5 days after intercourse as a device method.

ANSWER: A

Rationale:

Ethinyl estradiol increases hepatic synthesis of sex hormone-binding globulin (SHBG), a plasma carrier protein that binds circulating androgens (testosterone and, to a lesser extent, dihydrotestosterone) with high affinity. By raising SHBG levels, ethinyl estradiol increases the bound fraction of circulating androgens and correspondingly lowers the free, biologically active androgen fraction. Because it is the free androgen that acts on receptors in skin and hair follicles, this reduction in free androgen produces the clinical anti-androgenic benefit seen in acne and hirsutism. Higher ethinyl estradiol doses produce greater SHBG elevation, which is part of the rationale for selecting a 35-microgram EE preparation when a stronger anti-androgenic effect is desired, and the benefit is enhanced when the EE is paired with an anti-androgenic progestin.

• Option B: Option B is incorrect because ethinyl estradiol does not act as a competitive androgen receptor antagonist — direct androgen receptor blockade is the mechanism of anti-androgens such as spironolactone and cyproterone acetate, not of ethinyl estradiol, which works indirectly by raising SHBG.
• Option C: Option C is incorrect because ethinyl estradiol does not inhibit 5-alpha-reductase — that is the mechanism of finasteride and dutasteride; EE reduces free androgen availability through SHBG elevation rather than by blocking dihydrotestosterone formation.
• Option D: Option D is incorrect because ethinyl estradiol does not suppress adrenal cortisol or adrenal androgen synthesis as its mechanism of anti-androgenic benefit — the principal effect is hepatic SHBG induction, not adrenal suppression.
• Option E: Option E is incorrect because ethinyl estradiol does not lower androgen levels by accelerating renal clearance through competition for tubular reabsorption — testosterone is not cleared in this manner, and the anti-androgenic effect is mediated by increased SHBG binding that reduces the free androgen fraction.